Aromatase inhibitors: the journey from the state of the art to clinical open questions
Breast cancer is a major cause of death among females. Great advances have been made in treating this disease, and aromatase inhibitors (AIs) have been recognized as the cornerstone. They are characterized by high efficacy and low toxicity. The authors reviewed the available literature and defined s...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-12-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1249160/full |
| _version_ | 1827376553019834368 |
|---|---|
| author | Daniele Generali Daniele Generali Rossana Berardi Michele Caruso Marina Cazzaniga Marina Cazzaniga Ornella Garrone Ida Minchella Ida Paris Carmine Pinto Sabino De Placido |
| author_facet | Daniele Generali Daniele Generali Rossana Berardi Michele Caruso Marina Cazzaniga Marina Cazzaniga Ornella Garrone Ida Minchella Ida Paris Carmine Pinto Sabino De Placido |
| author_sort | Daniele Generali |
| collection | DOAJ |
| description | Breast cancer is a major cause of death among females. Great advances have been made in treating this disease, and aromatase inhibitors (AIs) have been recognized as the cornerstone. They are characterized by high efficacy and low toxicity. The authors reviewed the available literature and defined state-of-the-art AI management. This study was designed to assist clinicians in addressing the need to equally weigh patients’ needs and disease control rates in their everyday clinical practice. Today, AIs play a central role in the treatment of hormone receptor-positive breast cancer. In this study, an expert panel reviewed the literature on the use of AIs, discussing the evolution of their use in various aspects of breast cancer, from pre- and postmenopausal early breast cancer to metastatic breast cancer, along with their management regarding efficacy and toxicity. Given the brilliant results that have been achieved in improving survival in everyday clinical practice, clinicians need to address their concerns about therapy duration and the adverse effects they exert on bone health, the cardiovascular system, and metabolism. Currently, in addition to cancer treatment, patient engagement is crucial for improving adherence to therapy and supporting patients’ quality of life, especially in a selected subset of patients, such as those receiving an extended adjuvant or combination with targeted therapies. A description of modern technologies that contribute to this important goal is provided. |
| first_indexed | 2024-03-08T12:15:03Z |
| format | Article |
| id | doaj.art-85b79c44bf2a4bc88979bc2f337c12a6 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-08T12:15:03Z |
| publishDate | 2023-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-85b79c44bf2a4bc88979bc2f337c12a62024-01-22T14:34:09ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-12-011310.3389/fonc.2023.12491601249160Aromatase inhibitors: the journey from the state of the art to clinical open questionsDaniele Generali0Daniele Generali1Rossana Berardi2Michele Caruso3Marina Cazzaniga4Marina Cazzaniga5Ornella Garrone6Ida Minchella7Ida Paris8Carmine Pinto9Sabino De Placido10Breast Cancer Unit, Azienda Socio Sanitaria Territoriale di Cremona, Cremona, ItalyDepartment of Medical, Surgery and Health Sciences, University of Trieste, Trieste, ItalyMedical Oncology, Azienda Ospedaliera Universitaria (AOU) delle Marche, University Politecnica delle Marche, Ancona, ItalyHumanitas Istituto Clinico Catanese, Breast Centre Humanitas Catania, Catania, ItalySchool of Medicine and Surgery University of Milano Bicocca, Milan, ItalyPhase 1 Research Unit, Azienda Socio Sanitaria Territoriale (ASST) Monza, Monza, ItalyMedical Oncology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyDivision of Early Drug Development, European Institute of Oncology IRCCS, Milan, ItalyDepartment of Woman and Child Health and Public Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy0Medical Oncology Unit, Comprehensive Cancer Centre, Azienda Unità Sanitaria Locale - Istituto di Ricerca e Cura a Carattere Scientifico (AUSL-IRCCS) di Reggio Emilia, Reggio Emilia, Italy1Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalyBreast cancer is a major cause of death among females. Great advances have been made in treating this disease, and aromatase inhibitors (AIs) have been recognized as the cornerstone. They are characterized by high efficacy and low toxicity. The authors reviewed the available literature and defined state-of-the-art AI management. This study was designed to assist clinicians in addressing the need to equally weigh patients’ needs and disease control rates in their everyday clinical practice. Today, AIs play a central role in the treatment of hormone receptor-positive breast cancer. In this study, an expert panel reviewed the literature on the use of AIs, discussing the evolution of their use in various aspects of breast cancer, from pre- and postmenopausal early breast cancer to metastatic breast cancer, along with their management regarding efficacy and toxicity. Given the brilliant results that have been achieved in improving survival in everyday clinical practice, clinicians need to address their concerns about therapy duration and the adverse effects they exert on bone health, the cardiovascular system, and metabolism. Currently, in addition to cancer treatment, patient engagement is crucial for improving adherence to therapy and supporting patients’ quality of life, especially in a selected subset of patients, such as those receiving an extended adjuvant or combination with targeted therapies. A description of modern technologies that contribute to this important goal is provided.https://www.frontiersin.org/articles/10.3389/fonc.2023.1249160/fullaromatase inhibitorsbone losscardiotoxicitydrug adherencebreast cancer |
| spellingShingle | Daniele Generali Daniele Generali Rossana Berardi Michele Caruso Marina Cazzaniga Marina Cazzaniga Ornella Garrone Ida Minchella Ida Paris Carmine Pinto Sabino De Placido Aromatase inhibitors: the journey from the state of the art to clinical open questions Frontiers in Oncology aromatase inhibitors bone loss cardiotoxicity drug adherence breast cancer |
| title | Aromatase inhibitors: the journey from the state of the art to clinical open questions |
| title_full | Aromatase inhibitors: the journey from the state of the art to clinical open questions |
| title_fullStr | Aromatase inhibitors: the journey from the state of the art to clinical open questions |
| title_full_unstemmed | Aromatase inhibitors: the journey from the state of the art to clinical open questions |
| title_short | Aromatase inhibitors: the journey from the state of the art to clinical open questions |
| title_sort | aromatase inhibitors the journey from the state of the art to clinical open questions |
| topic | aromatase inhibitors bone loss cardiotoxicity drug adherence breast cancer |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1249160/full |
| work_keys_str_mv | AT danielegenerali aromataseinhibitorsthejourneyfromthestateofthearttoclinicalopenquestions AT danielegenerali aromataseinhibitorsthejourneyfromthestateofthearttoclinicalopenquestions AT rossanaberardi aromataseinhibitorsthejourneyfromthestateofthearttoclinicalopenquestions AT michelecaruso aromataseinhibitorsthejourneyfromthestateofthearttoclinicalopenquestions AT marinacazzaniga aromataseinhibitorsthejourneyfromthestateofthearttoclinicalopenquestions AT marinacazzaniga aromataseinhibitorsthejourneyfromthestateofthearttoclinicalopenquestions AT ornellagarrone aromataseinhibitorsthejourneyfromthestateofthearttoclinicalopenquestions AT idaminchella aromataseinhibitorsthejourneyfromthestateofthearttoclinicalopenquestions AT idaparis aromataseinhibitorsthejourneyfromthestateofthearttoclinicalopenquestions AT carminepinto aromataseinhibitorsthejourneyfromthestateofthearttoclinicalopenquestions AT sabinodeplacido aromataseinhibitorsthejourneyfromthestateofthearttoclinicalopenquestions |